c-FLIP is a well-described inhibitor of death receptor-mediated apoptosis (1) . At the mRNA level, it can be found in multiple splice variants, whereas at the protein level only three isoforms, c-FLIP L , c-FLIP S , and c-FLIP R , have been detected so far (1) (2) (3) (4) . All three c-FLIP isoforms contain two death eff ector domains (DEDs), which are structurally similar to the NH 2 -terminal part of procaspase-8. c-FLIP L also contains catalytically inactive caspase-like domains (p20 and p12).
c-FLIP proteins are recruited to the deathinducing signaling complex (DISC) by DED interactions (3) (4) (5) . Both short c-FLIP isoforms, c-FLIP S and c-FLIP R , block death receptorinduced apoptosis by inhibiting procaspase-8 activation at the DISC (2, 3) . The role of c-FLIP L at the DISC is still a matter of controversy (6, 7) . Some reports describe c-FLIP L as an antiapoptotic molecule, functioning in a way analogous to c-FLIP S , whereas others describe c-FLIP L as a proapoptotic molecule, facilitating the activation of procaspase-8 at the DISC. This proapoptotic role may explain the phenotype of c-FLIP-defi cient mice characterized by heart failure and death at embryonic day 10.5. The same phenotype has been reported for caspase-8-and FADD-defi cient mice (8) (9) (10) (11) .
In addition to its antiapoptotic role in death receptor-induced apoptosis, c-FLIP proteins were invoked to play a prominent role in NF-κB signaling (12) (13) (14) . The transcription factor NF-κB family regulates the expression of genes crucial for innate and adaptive immune responses, cell growth, and apoptosis (15) . In mammalian cells, the NF-κB family is composed of fi ve members: RelA, RelB, c-Rel, p50/NF-κB1, and p52/NF-κB2 (16) . In most cells, the NF-κB dimer is sequestered in the cytosol by inhibitors of the κB protein (IκB), and its nuclear translocation can be induced by a wide variety of stimuli (16) . These stimuli trigger activation of the IκB kinase (IKK) complex, which consists of two catalytic subunits, IKKα and IKKβ, as well as a regulatory subunit, IKKγ/NEMO. When the IKK complex is activated, IκB is phosphorylated, and the IκBs are degraded in a ubiquitin-dependent manner. The NF-κB dimers can then be translocated into the nucleus, where target gene transcription is induced.
Recently, it has been demonstrated that overexpression of c-FLIP L activates NF-κB (13, 17) . In another study, upon overexpression, c-FLIP L was shown to interact with established components of the TNFR-mediated NF-κB activation pathway, TRAF1, TRAF2, and RIP (12) . In addition, it has been reported that c-FLIP L -mediated NF-κB activation requires cleavage to p43-FLIP, also demonstrated to interact with TRAF2 (18) . In TNFR-mediated NF-κB activation, TRAF2 and RIP were described to act upstream of the IKK complex (19, 20) .
Here, we show that in nonapoptotic cells, c-FLIP forms heterodimers with procaspase-8 resulting in a novel NH 2 -terminal fragment of c-FLIP (p22-FLIP). p22-FLIP turned out to be the key mediator of NF-κB activation by direct binding to the IKK complex. These fi ndings provide a new mechanism of c-FLIP-mediated NF-κB activation and shed light on the regulation of life/death decisions made in lymphocytes.
RESULTS

A new form of c-FLIP can be detected in malignant B and T cells
In addition to the three previously described c-FLIP protein isoforms, c-FLIP L , c-FLIP R , and c-FLIP S (2, 3, 21) , we have detected a new prominent protein band with the anti-FLIP mAb NF6 directed against the DED region of c-FLIP (Fig.  1 A) . The molecular mass of this protein is ‫22ف‬ kD. The p22 protein was observed in total cellular lysates ( Fig. 1 A) and in immunoprecipitates (Fig. 1 B) from B lymphoblastoid cell lines Boe R and Raji and the T cell lines HUT78 and Jurkat A3, but not in CEM and SKW6.4 cells. The viability of the cells used for analysis was verifi ed by negative propidium iodide and annexin V staining (Fig. S1 , available at http://www.jem.org/cgi/content/full/jem.20051556/DC1). P22 protein was the most prominent in Boe R cells (Fig. 1, A and B). We call this protein p22-FLIP.
The detection of p22-FLIP with the anti-FLIP mAb NF6 indicated the presence of DEDs in p22-FLIP because the antibody was raised against the NH 2 terminus of c-FLIP. Furthermore, p22-FLIP disappeared upon the addition of zVAD-fmk (Fig. 1 C) . This suggests that p22-FLIP is likely a caspase-dependent cleavage product of c-FLIP. We then analyzed the primary structure of c-FLIP L/S and found an aspartate residue at position 198 (Fig. 1 D) . Cleavage at Asp 198 could result in the formation of an NH 2 -terminal DEDcontaining cleavage product with a molecular mass of ‫22ف‬ kD, corresponding to p22-FLIP.
To test this hypothesis, we generated a cDNA corresponding to the c-FLIP NH 2 -terminal fragment resulting from cleavage at Asp 198 . Subsequently, p22-FLIP was translated in vitro and added to cell lysates of Boe R cells, followed by immunoprecipitation with the anti-FLIP mAb NF6. The products of immunoprecipitation as well as the corresponding lysates were analyzed by Western blot (Fig. 1 E) . After adding the in vitro-translated c-FLIP NH 2 -terminal fragment, the band corresponding to p22-FLIP increased considerably. Thus, we conclude that the molecular mass of the in vitro-translated product was indeed identical to endogenous p22-FLIP. These data provide the fi rst evidence that p22-FLIP is an NH 2 -terminal cleavage product of c-FLIP generated by cleavage at Asp 198 .
p22-FLIP identifi cation as the NH 2 -terminal cleavage product of c-FLIP
To study whether p22-FLIP can be generated from both c-FLIP L and c-FLIP S , we performed the following experiment in vitro. c-FLIP L , c-FLIP S , and FLAG-c-FLIP L were translated in vitro, [ 35 S] labeled, and added to total cellular lysates of HUT78 and J16 cells (Fig. 2 A) . Upon incubation, all c-FLIPs were cleaved into the NH 2 -terminal fragment p22-FLIP (for c-FLIP L and c-FLIP S ), the NH 2 -terminal FLAGp22-FLIP (for FLAG-c-FLIP L ), and the COOH-terminal fragment p33-FLIP (for c-FLIP L and FLAG-c-FLIP L ). Consistent with the results obtained previously, p22-FLIP was not detected upon the addition of zVAD-fmk. Thus, we observed a caspase-dependent processing of c-FLIP L/S into p22-FLIP in nonapoptotic cells.
To provide conclusive evidence that p22-FLIP is indeed the cleavage product of c-FLIP resulting from cleavage at Asp 198 , we generated an uncleavable D198A mutant of FLAG-c-FLIP L . In vitro-translated [ 35 S]-labeled D198A-FLAG-c-FLIP L and WT-FLAG-c-FLIP L were added to the lysates of HUT78 cells (Fig. 2 B) . As anticipated, FLAG-p22-FLIP was generated in a caspase-dependent manner only from WT-FLAG-c-FLIP. In addition, Boe R cells were transfected with WT-and D198A-FLAG-c-FLIP constructs, and consistent with the in vitro data, FLAG-p22-FLIP generation was observed only in the cells transfected with the WT construct (Fig. 2 C) . Collectively, these data demonstrate that p22-FLIP is the NH 2 -terminal cleavage product of c-FLIP generated by caspase cleavage at Asp 198 .
p22-FLIP is generated by procaspase-8 activity and inhibits death receptor-induced apoptosis To unravel the mechanism of p22-FLIP formation and fi nd the caspase directly involved in c-FLIP processing, we investigated whether procaspase-8 might generate p22-FLIP. Procaspase-8, which, as a proform, was reported to possess catalytic activity (7, 22) and form heterodimers with c-FLIP in the cytosol by DED interactions, represented a likely candidate (6, 23) . Therefore, we immunoprecipitated procaspase-8 from HUT78 cells with an anti-caspase-8 mAb and added in vitrotranslated [ 35 S]-labeled c-FLIP L (Fig. 3 A, left) . Interestingly, we observed cleavage of c-FLIP L into the NH 2 -terminal fragment p22-FLIP and the COOH-terminal fragment p33-FLIP by procaspase-8. The processing was blocked by zVAD-fmk.
To ensure that the mature caspase-8 heterotetramer could not process c-FLIP into p22-FLIP, we added recombinant active caspase-8 to in vitro-translated c-FLIP L (Fig. 3 A,  right) . As expected, recombinant caspase-8 cleaves c-FLIP L in a "classic apoptotic" fashion and generated p43-FLIP and p12-FLIP. Thus, we show that caspase-8 and procaspase-8 process c-FLIP in two mutually exclusive ways. The active caspase-8 heterotetramer generates the well-characterized p43-FLIP and p12-FLIP cleavage products, whereas procaspase-8 activity induces formation of the novel p22-FLIP cleavage product as well as the COOH-terminal p33-FLIP. This is consistent with a report on diff erent substrate specifi cities of the caspase-8 proform and active caspase-8 (7). Clearly, the present study is the fi rst to demonstrate two diff erent caspase-8 specifi cities with respect to c-FLIP cleavage.
c-FLIP proteins are well-established inhibitors of death receptor-mediated apoptosis. To examine the role of p22-FLIP in death receptor-mediated apoptosis, we generated stable BJAB cell lines overexpressing either high (p22-FLIP high ) or low (p22-FLIP low ) amounts of p22-FLIP. The amount of p22-FLIP in these cell lines was validated by Western blot (Fig. 3 B) . Both p22-FLIP high and p22-FLIP low BJAB cells were characterized by reduced sensitivity toward CD95-and TRAIL-induced apoptosis as compared with the vectortransfected control (Fig. 3 , C and D, respectively). The reduction in apoptosis was more prominent in the p22-FLIP high cells. These data provide evidence that compared with other c-FLIP proteins, p22-FLIP is an even stronger inhibitor of death receptor-induced apoptosis.
c-FLIP proteins were reported to have a short half-life (24, 25) . We and others have demonstrated that cycloheximide (CHX) sensitizes cells toward death receptor-induced (24, 25) . To understand whether sensitization also involves a decrease of the p22-FLIP level, we studied Boe r cells that contain high levels of p22-FLIP. Treatment of Boe r cells with CHX resulted in a substantial decrease of the p22-FLIP level within 4 h (Fig. S2 A, available at http://www.jem. org/cgi/content/full/jem.20051556/DC1). This decrease correlated with an enhanced sensitivity toward CD95-and TRAIL-induced apoptosis (Fig. S2 B) . These data provide additional evidence that the p22-FLIP level in Boe r cells correlates with the sensitivity toward death receptor-induced apoptosis, pointing toward the inhibitory role of p22-FLIP.
The antiapoptotic action of c-FLIP in death receptormediated apoptosis involves inhibition of caspase-8 activation at the DISC (2, 3, 24) . To investigate whether p22-FLIP is also recruited to the DISC, we immunoprecipitated the CD95 DISC from p22-FLIP high cells. Indeed, p22-FLIP was recruited to the DISC (Fig. 3 E) . As expected, the activation of procaspase-8 at the DISC of p22-FLIP high cells was lower than in vector-transfected cells. The amount of caspase-8 cleavage products in the DISC, p43/p41, and p18 was markedly reduced in p22-FLIP high cells, whereas the amounts of FADD and CD95 were similar in both p22-FLIP high and vector-transfected cells. This observation is consistent with the reduced sensitivity of p22-FLIP high cells toward CD95-induced apoptosis and shows that p22-FLIP eff ectively blocks caspase-8 activation at the DISC, thereby inhibiting CD95-induced apoptosis. 
p22-FLIP is a strong inducer of NF-B
We established an inhibitory role of p22-FLIP in death receptor-induced apoptosis; however, the questions of why p22-FLIP is present in nonapoptotic malignant cells and which functional role p22-FLIP might play in the nonapoptotic scenario were not answered. Using NF-κB luciferase activation assays with p22-FLIP and c-FLIP L , we observed that p22-FLIP is a strong inducer of NF-κB (Fig.  4 A) . Moreover, p22-FLIP-mediated NF-κB activation was much stronger than that observed with c-FLIP L , even though expression levels of p22-FLIP and c-FLIP L were similar (Fig. 4 A) .
To clarify whether NF-κB activation correlates with the expression level of p22-FLIP, we performed transient transfections of 293T cells with p22-FLIP (Fig. 4 B) . The maximum of NF-κB activity at 10 h paralleled the increase of p22-FLIP expression. Moreover, the observed expression level of p22-FLIP in 293T cells (Fig. 4 B) compared with c-FLIP L was still lower as compared with the ratio p22-FLIP/ c-FLIP L in Boe R cells (Fig. 1 A) . Thus, we demonstrate that the induction of NF-κB is specifi c for p22-FLIP and does not depend on a high expression level of p22-FLIP.
We also assayed p22-induced NF-κB activity by electrophoretic mobility shift assay (EMSA; Fig. 4 C) , which independently confi rmed that p22-FLIP induces NF-κB. Thus, we demonstrated that p22-FLIP is a strong inducer of NF-κB.
p22-FLIP induces NF-B by direct interaction with the IKK complex
To get more insight into the mechanism of p22-mediated NF-κB induction, we coexpressed p22-FLIP with the inhibitors of NF-κB (IκBα and IκBβ) and with components of the IKK complex (IKKα, IKKβ, DN-IKKα, and DN-IKKβ; Fig. 5 A) . Cotransfections of p22-FLIP with increasing amounts of IκBα and IκBβ inhibited NF-κB activation. Looking at more upstream events, we observed that cotransfection with DN-IKKα and DN-IKKβ also led to suppression of NF-κB activation. Collectively, the results indicated that p22-FLIP is a strong inducer of NF-κB acting via the canonical NF-κB pathway.
We further examined whether p22-FLIP directly interacts with the IKK complex. FLAG-tagged IKKα, IKKβ, and IKKγ were transiently cotransfected with p22-FLIP into 293T cells, and then immunoprecipitated with anti-FLAG and anti-FLIP antibodies (Fig. 5 B) . We did not observe any interaction between p22-FLIP and IKKα or IKKβ. However, p22-FLIP was coimmunoprecipitated with FLAG-IKKγ and vice versa. Thus, we showed that p22-FLIP interacts with the IKK complex via IKKγ.
In addition, we compared NF-κB induction by p22-FLIP, c-FLIP L , and p43-FLIP upon transient transfections in 293T cells (Fig. 5 C) . Interestingly, the addition of zVADfmk resulted in a decrease in NF-κB activation for p43-FLIP and c-FLIP L , but did not aff ect p22-FLIP-mediated NF-κB induction. These results strongly indicate that p43-FLIP and c-FLIP L require further cleavage to induce NF-κB activity, whereas p22-FLIP does not. Thus, we show that for the induction of NF-κB activity, both p43-FLIP and c-FLIP L have to be processed into p22-FLIP. 293T cells were cotransfected with p22-FLIP, the luciferase reporter plasmid, and any one of the constructs IκBα, IκBβ, WT-IKKα, WT-IKKβ, mutated IKKα, or IKKβ (bottom part of the diagram). Transfection effi ciency was examined using GFP transfections. NF-κB luciferase activity was determined as described in Materials and methods. (B) FLAG or FLIP immunoprecipitations were performed from 293T cells that were transfected with p22-FLIP and any one of the constructs FLAG-IKKα, FLAG-IKKβ, or FLAG-IKKγ. Immunoprecipitated products were subjected to 12% SDS-PAGE gels and analyzed by Western blot using anti-FLIP mAb NF6 and anti-FLAG mAb. (C) 293T cells were cotransfected with MEKK1, p22-FLIP, c-FLIP L , p43-FLIP, and the luciferase reporter plasmid. Transfected cells were incubated for 16 h in the presence of the indicated concentrations of zVAD-fmk and lysed, and NF-κB luciferase activity was determined.
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p22-FLIP induces NF-B during activation of primary lymphocytes and maturation of primary DCs
Next, we examined primary human T and B cells for the presence of p22-FLIP. Interestingly, p22-FLIP was absent in freshly prepared cells, but was generated upon activation of these cells with PHA (Fig. 6 A) . The same phenomenon was observed in DCs. p22-FLIP was generated upon LPS stimulation, indicating that p22-FLIP is present during maturation of DCs (Fig. 6 A) . Also, the increase of p22-FLIP levels in primary cells correlated with the increase of c-FLIP levels and, correspondingly, with the increase of the ratio of c-FLIP to procaspase-8. This observation provides additional evidence for the proposed mechanism of procaspase-8-mediated c-FLIP cleavage to p22-FLIP (Fig. 3) .
To fi nd out whether p22-FLIP also directly interacts with the IKK complex in primary human T cells, we performed immunoprecipitations using an anti-IKKγ antibody (Fig.  6 B) . We observed p22-FLIP in the IKK complex. Thus, we conclude that p22-mediated NF-κB induction occurs via the same mechanism in primary cells.
To obtain more insight into the role of p22-FLIP in T cell activation, we studied the proliferation of primary T cells upon silencing of c-FLIP using small interfering RNA (siRNA). The silencing of c-FLIP resulted in down-regulation of c-FLIP L/S/R as well as its cleavage product, p22-FLIP (Fig.  6 C) . Primary T cells were stimulated with either PHA or anti-CD3/CD28, and thymidine incorporation was measured after 3 d of additional culture (Fig. 6 C) . Interestingly, silencing of c-FLIP led to a complete stop of cell proliferation. Thus, we show that the absence of c-FLIP and, consequently, p22-FLIP led to severe defects in T cell proliferation.
DISCUSSION
c-FLIP proteins were demonstrated to induce NF-κB activation (12) (13) (14) . However, the exact underlying mechanism of this process has not been established yet. In this study, we identifi ed a new mechanism of c-FLIP-mediated NF-κB activation and showed that NF-κB activation requires c-FLIP processing into the NH 2 -terminal DED-containing fragment, p22-FLIP (Fig. 7) . p22-FLIP is generated by procaspase-8 cleavage of both c-FLIP isoforms, c-FLIP L and c-FLIP S . Furthermore, p22-FLIP is a strong activator of NF-κB, acting directly at the level of the IKK complex by binding to IKKγ. In addition to its role as an activator of NF-κB, p22-FLIP can block apoptosis by directly binding to the DISC.
p22-FLIP is generated by cleavage of c-FLIP L/S at Asp 198 . The resulting NH 2 -terminal fragment, p22-FLIP, contains two tandem DEDs and has a high structural homology to v-FLIP of the Kaposi's sarcoma-associated herpesvirus and other v-FLIPs (14) that are also characterized by the presence of two DEDs followed by a short COOH terminus.
We argue that p22-FLIP is the fi nal cleavage product of c-FLIP that serves as a mediator of NF-κB activation. This result is in contrast to previous studies, where it was suggested that p43-FLIP is a cleavage product of c-FLIP that mediates NF-κB activation (18) . We have clearly shown that upon zVAD-fmk treatment, p43-FLIP-mediated activation of NF-κB is decreased, whereas the p22-FLIP-mediated NF-κB response remained unaltered. These results indicate that p43-FLIP requires further processing. Importantly, our study demonstrates a new NF-κB-activating pathway initiated by procaspase-8. We show that independently of death receptor stimulation, procaspase-8 generates the p22-FLIP cleavage product, which leads to the induction of NF-κB (Fig. 7) . Recently, procaspase-8 was reported to play a prominent role in NF-κB induction via its involvement in the MALT1-Bcl-10 adaptor complex that is formed upon TCR stimulation (26) . Our fi ndings further elucidate the involvement of procaspase-8 in NF-κB induction.
Interestingly, we could also show that the active mature caspase-8 heterotetramer p10 2 -p18 2 cleaves c-FLIP L in vitro to p43-FLIP and p12-FLIP, but not to p22-FLIP. Thus, we observe that procaspase-8 and caspase-8 heterotetramer cleave c-FLIP in two diff erent ways. This is consistent with reports upon diff erent substrate specifi cities of the caspase-8 proform and active caspase-8 (7). Of note, our study is the fi rst one demonstrating two diff erent caspase-8 specifi cities with respect to c-FLIP cleavage.
In addition, we have observed in primary cells that upon increase of the ratio of c-FLIP to procaspase-8, the amount of p22-FLIP was substantially increased. It is likely that procaspase-8 constitutively cleaves c-FLIP to p22-FLIP, forming dimers with c-FLIP. The formation of such dimers between procaspase-8 and c-FLIP in the cytosol was described previously (6, 23) . Thus, the ratio of procaspase-8 to c-FLIP in a particular cell type would be the crucial factor defi ning the amount of generated p22-FLIP and, correspondingly, the potential to induce NF-κB.
Our fi ndings provide a molecular mechanism for how c-FLIP and procaspase-8 contribute to the activation and proliferation of primary lymphocytes. It was reported that caspase activity is essential for T cell activation, as it was shown in experiments with caspase inhibitors (27, 28) . Analysis of caspase-8 and c-FLIP conditional knockout mice has demonstrated that those mice show severe defects in T cell activation and proliferation (29) . Caspase-8 was reported to be essential for antigen-induced NF-κB activation in T, B, and NK cells (26, 30, 31) . We show that upon silencing of c-FLIP in primary cells, the proliferation of these cells is impaired. This demonstrates the importance of our new p22-FLIP-mediated NF-κB-activating pathway in primary lymphocytes.
In conclusion, we described a new NF-κB-activating pathway, which is mediated by two well-described apoptotic DED-containing proteins: procaspase-8 and c-FLIP via their cleavage product, p22-FLIP. The balance between DEDcontaining proteins may provide sensitive signaling check points that cells use for signaling cross-talk and switching between apoptosis-resistant and -sensitive phenotypes and, thus, between life and death.
MATERIALS AND METHODS
Cell lines. The T cell lines HUT78, CEM, H9, Jurkat (clone A3), and Jurkat (clone J16); the B lymphoblastoid cell lines SKW6.4, Raji, and BJAB; and the pre-B cell line Boe R were maintained in RPMI 1640, 10 mM Hepes, 50 μg/ml gentamycin, and 10% fetal calf serum (all from Life Technologies) in 5% CO 2 . 
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Antibodies and reagents. Anti-FADD mAb (IgG1) was purchased from Transduction Laboratories. Anti-FLAG mAb was purchased from SigmaAldrich. Anti-CD95 polyclonal antibody C20 was purchased from Santa Cruz Biotechnology, Inc. Anti-caspase-8 mAb C15 (mouse IgG2b) recognizes the p18 subunit of caspase-8 (32). Anti-IKKα/β and anti-IKKγ antibodies were purchased from Santa Cruz Biotechnology, Inc., and anti-ERK1 mAb was purchased from BD Biosciences. Anti-APO-1 is an agonistic mAb (IgG3, κ) recognizing an epitope on the extracellular part of CD95 (APO-1/Fas; reference 33). FLAG-TRAIL was obtained from H. Walczak (DKFZ, Heidelberg, Germany). Horseradish peroxidase-conjugated goat anti-mouse IgG1, IgG2a, and IgG2b were from SouthernBiotech. All chemicals used were of analytical grade and purchased from Merck or Sigma-Aldrich. Plasmids encoding c-FLIP L and c-FLIP S have been described previously (2) . The plasmid encoding FLAG-c-FLIP L has also been described (3). NF-κB reporter plasmid was provided by M. Li-Weber (DKFZ, Heidelberg, Germany). Constructs of FLAG-IKKα, FLAG-IKKβ, DN-FLAG-IKKα (Κ44Α), and DN-FLAG-IKKβ (Κ44Α) were provided by H. Nakano (Juntendo University, Tokyo, Japan).
EMSA. Soluble nuclear proteins were prepared and used for EMSA as described previously (34) . For each reaction, 10-20 fmol of 32 
P-labeled oligonucleotides comprising an NF-κB binding site (5′-T C A G A G G G G A C-T T T C C G A G A G G C G -3′) or NF-Y binding site (5′-C A C C T T T T A A C C-A A T C A G A A A A A T -3′) were used.
Cloning of p22-FLIP and D198A-FLAG-c-FLIP L . p22-FLIP was cloned into the pEF4 expression vector (Invitrogen) using the PCR and the following primers: sense (encoding the KpnI restriction site): 5′-ggggtacccc-
A T G T C T G C T G A A G T C A T C C -3′ and antisense (encoding the XbaI restriction site): 5′-gctctagagcctaA T C C T T G A G A C T C T T T T G G -3′.
The D198A-FLAG-c-FLIP L mutant was cloned via overlap-PCR into the pEF4 expression vector (Invitrogen). The NH 2 -terminal part was amplifi ed using the following: forward primer 1: 5′-ggggtaccccA T Immunoprecipitates were used for in vitro assay or analyzed using SDS-PAGE gels (35) . Gels were transferred to Hybond nitrocellulose membrane (GE Healthcare), blocked with 5% nonfat dry milk in PBS/ Tween (PBS plus 0.05% Tween 20) for 1 h, washed with PBS/Tween, and incubated with the primary antibody in PBS/Tween overnight at 4°C. Blots were developed with a chemoluminescence method according to the manufacturer's protocol (PerkinElmer).
G G A C T A C A-A G G A C G A C G A C A A G G G G A T G T C T G C T G A A G T C A T C C A T C A G G -3′; reverse primer 1: 5′-C C T G A A A G T T A T T T G A A G G T G C C T T G A G A C T-C T T T T G G -
Immunoprecipitations. For c-FLIP immunoprecipitation, 5 × 10 7 cells were lysed in a volume of 1 ml for 30 min at 0°C, followed by the addition of 100 μl NF6 hybridoma supernatant together with 30 μl protein ASepharose. For FLAG immunoprecipitation, 2 × 10 6 cells were transfected using the calcium phosphate method 1 d before lysis. Immunoprecipitation was performed by using 4 μg anti-FLAG mAb together with 30 μl protein A-Sepharose. For IKKγ immunoprecipitation, 10 7 primary human T cells were lysed with or without stimulation, and the immunoprecipitation was performed by using 2 μg anti-IKKγ mAb together with 30 μl protein ASepharose. Immunoprecipitations were performed for 1 h at room temperature or overnight at 4°C. Beads were then washed fi ve times with 20 volumes of lysis buff er and subjected to Western blot analysis as described above.
In vitro c-FLIP cleavage assays. Lysates of the indicated cell lines were prepared as described above and incubated with in vitro-translated [ 35 S]-labeled c-FLIP L , FLAG-c-FLIP L , D198A-FLAG-c-FLIP L , or c-FLIP S (TNT, T7-coupled reticulocyte lysate system; Promega) overnight at 4°C (36) . The procaspase-8 cleavage assay was performed as follows: 5 × 10 7 HUT78 cells were lysed, and procaspase-8 was immunoprecipitated using 100 μl anticaspase-8 C15 hybridoma together with 30 μl protein A-Sepharose. Beads with bound procaspase-8 were incubated in reaction buff er (50 mM Hepes, pH 7.4, 100 mM NaCl, 0.1% CHAPS, 10 mM dithiothreitol, and 10% sucrose) for 1 h at 37°C together with in vitro-translated c-FLIP L . The recombinant caspase-8 cleavage assay was performed as follows: 5 or 50 ng/ml recombinant caspase-8 was incubated in reaction buff er for 1 h at 37°C together with in vitro-translated c-FLIP L . Reactions were separated on 12% SDS-PAGE gels, blotted, and subjected to autoradiography. Preparation and activation of primary human lymphocytes and DCs. Human peripheral T and B cells were prepared as described previously (37) . For activation, resting primary human T cells (day 0) were cultured at 2 × 10 6 cells/ml with 1 μg/ml PHA for 16 h (day 1), and primary human B cells (day 0) were cultured at 2 × 10 6 cells/ml with 2 μg/ml PHA. After preparing lymphocytes, the primary human monocytes were isolated using cell adhesion onto cell culture fl asks. Leukocytes were resuspended in 20-30 ml RPMI 1640 with 10% FCS, and 2-ml aliquots were seeded into six-well titer plates. After incubation for 1 h, adherent cells were washed with PBS. Monocytes were diff erentiated into immature DCs by adding 1% human AB serum, 1% donor plasma, 1,000 U/ml GM-CSF (Schering), and 500 U/ml IL-4 (Immunotools) for 3 d. Cytokines were renewed after 3 d for an additional 3 d, and immature DCs were stimulated with 500 ng/ml LPS for 16 h. CHX experiments. For CHX treatments, cells were incubated with 10 μg/ml CHX for the indicated periods of time. For assaying apoptosis in a cytotoxicity assay, 10 6 cells were pretreated with 10 μg/ml CHX for 4 h, washed, and incubated with the indicated concentrations of 1 μg/ml anti-APO-1 or 50 ng/ml FLAG-TRAIL for 16 h at 37°C in 24-well plates. Cell death was measured by FSC/SSC via fl ow cytometry, and specifi c cell death was calculated as follows: (percentage of experimental cell death − percentage of spontaneous cell death)/(100 − percentage of spontaneous cell death) × 100.
Transfection of BJAB and
Annexin V and propidium iodide staining. To detect phosphatidylserine exposure by fl ow cytometry, the T and B cell lines were washed once with PBS, incubated for 10 min on ice in 400 μl binding buff er (2.5 mM Hepes-NaOH, pH 7.4, 35 mM NaCl, and 0.625 mM CaCl 2 ) with 1 μl annexin V-FITC (Qbiogene) or 10 μg/ml propidium iodide (Invitrogen), and analyzed via fl ow cytometry. 
